Foley, David A.

Abstract Aims We aimed to assess regression and development rates of ≥moderate secondary mitral regurgitation (MR) and tricuspid regurgitation (TR) in patients with heart failure and reduced ejection fraction (HFrEF) receiving contemporary guideline-directed medical therapy (GDMT). Methods Patients with a <1 year diagnosis of HFrEF with mildly (40% ≤ EF < 50%) or moderately (<40%) reduced EF enrolled in GDMT titration programme 2019–2024 were identified. Regression rates of ≥moderate MR/TR to ≤mild and development rates of incident ≥moderate MR/TR were calculated. Results Among 844 patients [median age 64; 68% men; 26% mildly reduced EF; 24% New York Heart Association (NYHA) Class III/IV], 28% had ≥moderate MR and 14% had ≥moderate TR. Over median 7.1 months, 171 (75%) patients with ≥moderate MR and 87 (75%) of patients with ≥moderate TR experienced regression to no/mild MR and TR, respectively. Conversely, over median 13 months, incident ≥moderate MR and TR developed in 5% and 6%, respectively, of patients with no/mild baseline MR and TR. Number of GDMT medications at follow-up was less in patients who did not have MR/TR regression (vs who did) and in patients who developed MR/TR (vs who did not). Patients with NYHA Class I/II received a similar number of GDMT and had a similar rate of MR and TR regression and development vs patients with NYHA Class III/IV. However, patients with mildly reduced EF received less GDMT medications vs patients with moderately reduced EF and experienced less MR regression. Conclusion In patients with a recent diagnosis of HFrEF receiving contemporary GDMT, the majority with ≥moderate secondary MR and TR achieved regression of MR/TR, and the minority without significant baseline MR/TR developed ≥moderate regurgitation at follow-up.

Background: Although dynamic left ventricular outflow tract (LVOT) obstruction is a hallmark for hypertrophic obstructive cardiomyopathy (HOCM), it can occur in other conditions. The aim of this study was to determine underlying conditions and clinical importance of LVOT obstruction in patients without HOCM. Methods: We reviewed the echocardiographic and clinical data of patients who underwent transthoracic echocardiography in Mayo Clinic Rochester from October 2001 to August 2006, and had LVOT peak pressure gradient (PG) > 25mmHg at rest. Results: Of 719 patients identified, 159 (22 %) patients had dynamic LVOT obstruction without HOCM (77 men; mean age, 66.6 ± 12.9 years). Main presenting symptoms were chest pains in 95 (59.7 %), and dyspnea in 46 (28.9 %). LVOT PG was 51 ± 24 mmHg at rest and 68 ± 27 mmHg after provocation. In 114 (71.7 %) patients, early diastolic transmitral inflow velocity (E) and early diastolic mitral annular tissue velocity (Ea) were obtained. Mean E, Ea, and E/Ea were 105 ± 47 cm/s, 6.4 ± 5.7 cm/s, and 18.3 ± 11.0, respectively. Systolic anterior motion of mitral apparatus was observed in 100 (62.9 %) patients. Concentric increase in LV wall thickness or LVH was most common condition present in 57 patients (36%). The cause of LVH was hypertension in 40 (70.1%), aortic stenosis in 8 (14.0%), and chronic renal failure in 4 (7.0%). In these patients, major precipitating factors were hyperdynamic LV systolic function in 54 (94.7%), use of vasodilator in 34 (59.6%) and small LV cavity in 30 (52.6%). Other prominent associated conditions were basal septal hypertrophy, mitral valve repair, cardiac amyloid, and apical ballooning. There were 28 (17.6%) all-cause mortalities during follow up (25 ± 17 months) including malignancy in 6 (21.4 %), sudden cardiac deaths in 4 (14.3 %), congestive heart failure in 3 (10.7 %). Conclusions: Dynamic LVOT obstruction can be found in patients without HOCM. The most common condition to develop dynamic LVOT obstruction without HOCM, is concentric increase in LV wall thickness in the setting of hyperdynamic motion, small LV cavity, and use of vasodilator. Other conditions which predispose patients for dynamic LVOT obstruction are hypovolemia, cardiac amyloidosis, apical ballooning syndrome, and mitral valve repair.

Papillary fibroelastomas (PFEs) are benign cardiac tumors arising from endocardium. They are commonly found on valvular surfaces and average 1.0–1.5 cm in size. Though often asymptomatic, PFEs can lead to potentially severe complications, primarily due to their embolic potential. Surgical resection is recommended for all symptomatic or large PFEs. We report the case of a patient presenting with cardiovascular symptoms who was found to have a very large aortic valve PFE, as diagnosed by histopathologic examination following surgical resection. Multimodality cardiovascular imaging demonstrates the classic morphologic findings, including a pedunculated appearance and oscillating “frond-like” surface projections.

Background and Purpose— Association of mitral valve prolapse (MVP) with ischemic neurological events (INEs) is uncertain. Methods— In the community of Olmsted County (Minn), we identified all MVP diagnosed (1989 to 1998) in patients in sinus rhythm with no prior history of INE. We measured INE rates and compared them with expected rates in our community to define the excess risk of INE. Results— Among 777 eligible subjects (age, 49±20 years; 66% female; follow-up, 5.5±3.0 years), 30 patients had at least 1 INE during follow-up (at 10 years, 7±1%). Compared with expected INEs in the same community, subjects with MVP showed excess risk of lifetime INE (relative risk [RR], 2.2; 95% CI, 1.5 to 3.2; P <0.001) and during follow-up under purely medical management (RR, 1.8; 95% CI, 1.1 to 2.8; P =0.009). Independent determinants of INE were older age (RR, 1.08 per year; 95% CI, 1.04 to 1.11; P <0.001), mitral thickening (RR, 3.2; 95% CI, 1.4 to 7.4; P =0.008), atrial fibrillation (AFib) during follow-up (RR, 4.3; 95% CI, 1.9 to 10.0; P <0.001), and need for cardiac surgery (RR, 2.5; 95% CI, 1.1 to 5.8; P =0.03). INE 10-year rates were low in patients <50 years of age (0.4±0.4%, P =0.60 versus expected) but were excessive in patients >50 years of age (16±3%, P <0.001 versus expected) or with thickened leaflets (7±2%, P <0.001 versus expected). Predictors of follow-up AFib were age, mitral regurgitation, and left atrium diameter (all P <0.01). Conclusions— In the community, subjects with MVP display a lifetime excess rate of INE compared with expected. Clinical (older age) and echocardiographic (leaflets thickening) characteristics define patients with MVP at high risk for INE, and subsequent AFib or need for cardiac surgery, both related to the degree of mitral regurgitation, increase the risk of INE.